Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
about
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers.Problem or solution: The strange story of glucagon.Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids.Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemiaFuture Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
P2860
Q47625288-01F93A3E-CCD1-4242-9E77-80B85BAF8469Q48171528-8FA574BB-70F5-4E72-BA8B-D2D1296FD64FQ48326278-DD3E7067-F1C7-45FF-8F01-B2D615BAA3FBQ50140641-CCC50F2B-58FE-41DB-A837-F13F823069FEQ50156613-D3E40D56-ED3F-457C-B65C-775A89EDBEC2Q55032630-9FCEB878-C539-4AB9-B648-68B60170AA20Q58732217-2C9103C0-C595-4B50-B645-1AD65A38DC68Q59136513-3EC8A05B-1515-414B-8F6C-6FE6F61233C7
P2860
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Treatment with LY2409021, a gl ...... patients with type 2 diabetes.
@en
Treatment with LY2409021, a gl ...... patients with type 2 diabetes.
@nl
type
label
Treatment with LY2409021, a gl ...... patients with type 2 diabetes.
@en
Treatment with LY2409021, a gl ...... patients with type 2 diabetes.
@nl
prefLabel
Treatment with LY2409021, a gl ...... patients with type 2 diabetes.
@en
Treatment with LY2409021, a gl ...... patients with type 2 diabetes.
@nl
P2093
P2860
P356
P1476
Treatment with LY2409021, a gl ...... patients with type 2 diabetes
@en
P2093
Arie Regev
Christof Kazda
Cristina B Guzman
Naga Chalasani
Parag Garhyan
Sudha Shankar
Thomas A Hardy
Xiaotian M Zhang
P2860
P304
P356
10.1111/DOM.12958
P577
2017-06-08T00:00:00Z